The treatment of Raynaud's phenomenon

Clinics in Dermatology - Tập 12 - Trang 317-321 - 1994
James R. Seibold1, Nancy E. Allegar1
1From the Clinical Pharmacology Unit, UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA

Tài liệu tham khảo

Rodeheffer, 1983, Controlled double-blind trial of nifedipine in the treatment of Raynaud's phenomenon, N Engl J Med, 308, 880, 10.1056/NEJM198304143081507

Coffman, 1989, Treatment, 7, 127

Yocum, 1985, Use of biofeedback training in treatment of Raynaud's disease and phenomenon, J Rheumatol, 12, 90

Keefe, 1980, Biofeedback, autogenic training and progressive relaxation in the treatment of Raynaud's disease, J Appl Behav Anal, 13, 3, 10.1901/jaba.1980.13-3

Jobe, 1982, Induced vasodilation as treatment for Raynaud's disease, Ann Intern Med, 97, 706, 10.7326/0003-4819-97-5-706

Snyder, 1985, Calcium-antagonist drugs. Receptor interactions that clarify therapeutic effects, N Engl J Med, 313, 995, 10.1056/NEJM198510173131606

Malamet, 1985, Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation, Am J Med, 78, 602, 10.1016/0002-9343(85)90402-4

Shepherd, 1985, Spasm of the coronary arteries: Causes and consequences (the scientist's viewpoint), 60, 33

Seibold, 1984, Treatment of Raynaud's phenomenon with ketanserin, a selective antagonist of the serotonin2 (5-HT2) receptor, Arthritis Rheum, 27, 139, 10.1002/art.1780270204

Seibold JR, Clements PJ, Medsger TA, et al. Multicenter double-blind parallel study of ketanserin in the treatment of systemic sclerosis. Arthritis Rheum (in press).

Seibold, 1986, Selective antagonism of S2-serotonergic receptors relieves but does not prevent cold induced vasoconstriction in primary Raynaud's phenomenon, J Rheumatol, 13, 337

Martin, 1980, Prostaglandin E1 (PGE1) in the treatment of systemic sclerosis, Ann Rheum Dis, 39, 194

Mohrland, 1985, A multicenter placebo-controlled, double-blind study of prostaglandin E1 in Raynaud's syndrome, Ann Rheum Dis, 44, 754, 10.1136/ard.44.11.754

Shiokawa, 1986, Clinical evaluation of Lipo PGE1 in the treatment of peripheral circulatory involvement associated with collagen diseases, Jpn J Inflamm, 6, 83

Wigley, 1992, Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis, J Rheumatol, 19, 1407

Wigley FM, Wise RA, Seibold JR, et al. A multi-center placebo-controlled double-blind study of intravenous iloprost infusion in patients with Raynaud's phenomenon secondary to systemic sclerosis. Ann Intern Med (in press).

Engelhart, 1990, The effect of local temperature versus sympathetic tone on digital perfusion in Raynaud phenomenon, Angiology, 41, 715, 10.1177/000331979004100906

Surwit, 1984, A double-blind study of prazosin in the treatment of Raynaud's phenomenon in scleroderma, Arch Dermatol, 120, 329, 10.1001/archderm.120.3.329

Seibold, 1993, Methyl pyridine-3-carboxylate (MPC) cream in primary Raynaud's disease, Clin Pharmacol Ther, 53, 154

Krystal, 1992, Dose-response relationship for oral idazoxan effects in healthy human subjects: Comparison with yohimbine, Psychopharmacol, 108, 313, 10.1007/BF02245117

Herrick AL, Oogarah PK, Freemont AJ, et al. Vasculitis in patients with systemic sclerosis and severe digital ischemia requiring amputation. Ann Rheum Dis (in press).

Hart, 1989, Regulation of plasminogen activators and their inhibitors in rheumatic diseases: New understanding and the potential for new directions, J Rheumatol, 16, 1184

Thông tin
Thông tin xuất bản

Clinics in Dermatology

Tập 12

317-321

Thông tin tác giả